1-Apr-2026 3:30 PM CST - Business Wire Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin
24-Mar-2026 12:46 PM CST - Yahoo Finance New Zealand COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care market.
24-Mar-2026 6:04 AM CST - Seeking Alpha Cencora to buy EyeSouth Partners' retina business for $1.1B Cencora (COR) stock is in focus as the company agrees to buy EyeSouth retina business for $1.1B via its Retina Consultants of America unit. Read more here.
23-Mar-2026 6:17 AM CST - Reuters Cencora to buy retina business of EyeSouth Partners for $1.1 billion March 23 (Reuters) - Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit. The deal will bring EyeSouth's retina doctors into Cencora's own eye-care arm,
22-Mar-2026 12:26 PM CST - Yahoo Finance Cencora CFO Retirement Puts Capital Allocation And Growth Plans In Focus Cencora (NYSE:COR) announced the planned retirement of Chief Financial Officer and Executive Vice President James F. Cleary. The company has begun a leadership transition process and initiated an executive search to identify his successor.
17-Mar-2026 10:12 AM CST - Benzinga Cencora CFO Jim Cleary to retire after years of driving growth Cencora, Inc. COR shares are down during Tuesday's trading session as the company announced a leadership transition. Cencora CFO James Cleary To Retire Cencora's Chief Financial Officer, James Cleary,
10-Mar-2026 11:30 AM CST - Seeking Alpha Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Good morning, everybody. Thank you for our next presentation. We're obviously excited to have Cencora here with us today. For those of you who don't know me, I'm Glen Santangelo. I'm the analyst at Barclays that covers the stock. We recently picked up the ...
10-Mar-2026 9:30 AM CST - Benzinga Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years Cencora (NYSE:COR) has outperformed the market over the past 10 years by 9.6% on an annualized basis producing an average annual return of 22.42%. Currently, Cencora has a market capitalization of $69.
6-Mar-2026 9:52 AM CST - Yahoo Finance Is Cencora Stock Outperforming the S&P 500? Due to Cencora's outperformance relative to the broader S&P 500 Index, Wall Street analysts remain strongly optimistic about the stock's outlook.
Latest COR Trades by Congress Members
12-MAY-2025 - Jefferson Shreve, IN (District 6) sold between $50,001 and $100,000.
1-Apr-2026 3:30 PM CST - Business Wire Cencora Announces Date and Time for Second Quarter Fiscal 2026 Earnings Release Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2026 on Wednesday, May 6, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 6, 2026. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Fin
24-Mar-2026 12:46 PM CST - Yahoo Finance New Zealand COR to Expand Retina Consultants of America With $1.1B EyeSouth Deal Cencora is acquiring EyeSouth's retina business for $1.1 billion, expanding its RCA platform to strengthen foothold in the fast-growing eye care market.
24-Mar-2026 6:04 AM CST - Seeking Alpha Cencora to buy EyeSouth Partners' retina business for $1.1B Cencora (COR) stock is in focus as the company agrees to buy EyeSouth retina business for $1.1B via its Retina Consultants of America unit. Read more here.
23-Mar-2026 6:17 AM CST - Reuters Cencora to buy retina business of EyeSouth Partners for $1.1 billion March 23 (Reuters) - Drug distributor Cencora said on Monday it would buy the retina business of eye care network EyeSouth Partners for $1.1 billion, expanding its eye care unit. The deal will bring EyeSouth's retina doctors into Cencora's own eye-care arm,
22-Mar-2026 12:26 PM CST - Yahoo Finance Cencora CFO Retirement Puts Capital Allocation And Growth Plans In Focus Cencora (NYSE:COR) announced the planned retirement of Chief Financial Officer and Executive Vice President James F. Cleary. The company has begun a leadership transition process and initiated an executive search to identify his successor.
17-Mar-2026 10:12 AM CST - Benzinga Cencora CFO Jim Cleary to retire after years of driving growth Cencora, Inc. COR shares are down during Tuesday's trading session as the company announced a leadership transition. Cencora CFO James Cleary To Retire Cencora's Chief Financial Officer, James Cleary,
10-Mar-2026 11:30 AM CST - Seeking Alpha Cencora, Inc. (COR) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Good morning, everybody. Thank you for our next presentation. We're obviously excited to have Cencora here with us today. For those of you who don't know me, I'm Glen Santangelo. I'm the analyst at Barclays that covers the stock. We recently picked up the ...
10-Mar-2026 9:30 AM CST - Benzinga Here's How Much You Would Have Made Owning Cencora Stock In The Last 10 Years Cencora (NYSE:COR) has outperformed the market over the past 10 years by 9.6% on an annualized basis producing an average annual return of 22.42%. Currently, Cencora has a market capitalization of $69.
6-Mar-2026 9:52 AM CST - Yahoo Finance Is Cencora Stock Outperforming the S&P 500? Due to Cencora's outperformance relative to the broader S&P 500 Index, Wall Street analysts remain strongly optimistic about the stock's outlook.
